TENX - Phase III data for LEVO-CTS Trial due this month. Drug already approved outside of North America (Simdax) and has been used in over 1 million patients so success of trial is de-risked.
$50M market cap
28M shares outstanding, 17M Float
Almost 40% institutional ownership with likes of Sabby, Broadfin and Baker Brothers.
Stock just over $2 with 52-wk range of $1.21-2.94.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.